N/A
N=162
Study of Certain Prevail Implants Used to Treat All Types of Edentulism in the Maxilla and Mandible
Partial Edentulism
Bottom Line
View on ClinicalTrials.gov: NCT00728884 ↗Enrolled (actual)
162
Serious AEs
0.0%
Results posted
Aug 2009
Primary outcome: Primary: Osseous Integration — 145 participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- ZimVie
- Primary completion
- Jul 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Osseous Integration |
145 | — |
| SECONDARY Crestal Bone Resorption |
— | — |
Summary
This observational, prospective clinical study evaluates the performance of the Certain Prevail implant system to show potential crestal bone and soft tissue preservation following the crestal bone. It will also evaluate implant performance.
Study (null) hypothesis: The preservation of crestal bone for the Certain Prevail implants will be the same as that for standard non-platform switched implants from contemporaneous studies (historical controls).
Eligibility Criteria
Inclusion Criteria
- patients of either sex and any race greater than 18 years of age
- patients for whom a decision has already been made to use dental implants for treating an existing dental condition specifically:
- dental implants restored as single tooth replacements, short and long fixed bridges, overdenture, or fixed full denture.
- a temporary healing abutment will be placed on implant during implant placement surgery (single stage procedure).
- patients must be physically able to tolerate conventional surgical and restorative procedures
- patients must agree to be evaluated for each study visit, especially the yearly follow-up visit
Exclusion Criteria
- patients with active infection or severe inflammation in the areas intended for implant placement
- patients with a >10 cigarette per day smoking habit
- patients with uncontrolled diabetes mellitus
- patients with metabolic bone disease
- patients who have had treatment with therapeutic radiation to the head within the past 12 months
- patients in need of allogenic bone grafting at the site of the intended study implant for augmentation purposes. Grafting for treatment of dehiscence or fenestration must have occurred at least 8 weeks prior to implant placement surgery
- patients who are pregnant at the screening visit
- patients with evidence of severe para-functional habits such as bruxing or clenching
- patients with less than 6 weeks of healing time post tooth extraction at the intended treatment site
Data sourced from ClinicalTrials.gov (NCT00728884). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.